ABT

AI Research

XIENCE Skypoint India launch + Exact Sciences acquisition closing Q2 2026

Abbott Laboratories launched the XIENCE Skypoint stent in India for advanced cardiovascular treatment, and reported strong AFib ablation device clinical results with Volt showing 84.2% freedom from rhythm recurrence in PAF at 12 months. The company projects 2026 organic sales growth of 6.5–7.5% with adjusted diluted EPS of $5.55–$5.80, and the Exact Sciences acquisition is expected to close in Q2 2026, expanding its diagnostics capabilities. Trading near $112 with 22 analysts rating it a Buy and a 12-month target of $132.64, ABT offers approximately 19% upside potential.